{"prompt": "['6', 'GLEnmark', 'A new way for new world', 'A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and', 'Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo', 'Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic', 'Rhinitis (SAR)', 'Identifiers', 'NCT03463031', 'Date of Document', '18 July 2018', 'Confidential', 'Page 1 of 1']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'C', 'glenmank', 'GSP 301 NS', 'GSP 301-305', 'A DOUBLE-BLIND, RANDOMIZED, PARALLEL-', 'GROUP STUDY TO EVALUATE THE EFFICACY,', 'SAFETY AND TOLERABILITY OF FIXED DOSE', 'COMBINATION GSP 301 NASAL SPRAY COMPARED', 'WITH PLACEBO NASAL SPRAY IN PEDIATRIC', 'SUBJECTS (AGED 6 TO UNDER 12 YEARS) WITH', 'SEASONAL ALLERGIC RHINITIS (SAR).', 'Phase of Development', 'Phase 3', 'Sponsor', 'Glenmark Specialty SA', 'Avenue L\u00e9opold-Robert 37', '2300 La Chaux-de-Fonds', 'Switzerland', 'Study Number', 'GSP 301-305', 'IND Number', '123164', 'Approved by', 'Protocol Version', 'Version 3.0', 'Date', '18-Jul-2018', 'Supersedes', 'Version 2.0, 05-Apr-2018', 'Statement of Confidentiality', 'This protocol is a confidential document owned by Glenmark (Sponsor). Any unpublished information', 'contained in it may not be disclosed to a third party without prior written approval of the Sponsor.', 'However, the document may be disclosed to an Institutional Review Board/Independent Ethics', 'Committee or a statutory regulatory authority under a similar condition of confidentiality.', 'This study must be conducted in accordance with International Council on Harmonisation (ICH)', 'guidelines on Good Clinical Practice (GCP) and with the applicable regulatory requirements.', 'Glenmark', 'CONFIDENTIAL', 'Page 1 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', \"INVESTIGATOR'S AGREEMENT\", 'I have received and read the Investigational Brochure for fixed dose combination (FDC) of', 'olopatadine hydrochloride and mometasone furoate nasal spray (GSP 301 NS). I have read the', 'GSP 301-305 protocol and agree to conduct the study as outlined. I agree to maintain the', 'confidentiality of all information received or developed in connection with this protocol.', 'Printed Name of Investigator', 'Signature of Investigator', 'Date', 'Glenmark', 'CONFIDENTIAL', 'Page 2 of 90']\n\n###\n\n", "completion": "END"}